JP2018526450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526450A5 JP2018526450A5 JP2018531280A JP2018531280A JP2018526450A5 JP 2018526450 A5 JP2018526450 A5 JP 2018526450A5 JP 2018531280 A JP2018531280 A JP 2018531280A JP 2018531280 A JP2018531280 A JP 2018531280A JP 2018526450 A5 JP2018526450 A5 JP 2018526450A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- promoter
- composition according
- early
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562215651P | 2015-09-08 | 2015-09-08 | |
| US62/215,651 | 2015-09-08 | ||
| PCT/KR2016/009866 WO2017043815A1 (en) | 2015-09-08 | 2016-09-02 | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526450A JP2018526450A (ja) | 2018-09-13 |
| JP2018526450A5 true JP2018526450A5 (cg-RX-API-DMAC10.html) | 2019-08-29 |
| JP6895968B2 JP6895968B2 (ja) | 2021-06-30 |
Family
ID=58240110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531280A Expired - Fee Related JP6895968B2 (ja) | 2015-09-08 | 2016-09-02 | サイトカインおよびカルボキシルエステラーゼを発現する腫瘍溶解性改変ワクシニアウイルス、および、その使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10646524B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3347460A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6895968B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102674362B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN108350434B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2016320355B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2996120C (cg-RX-API-DMAC10.html) |
| HK (1) | HK1255192A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017043815A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| AU2016313969B2 (en) * | 2015-06-19 | 2021-12-23 | Sillajen, Inc. | Compositions and methods for viral embolization |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| WO2018182014A1 (ja) * | 2017-03-31 | 2018-10-04 | 久修 緒方 | 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤 |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| CN109554353B (zh) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| JP2021511060A (ja) * | 2018-01-26 | 2021-05-06 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
| CA3176812A1 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CA3112654A1 (en) * | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| KR20220004959A (ko) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아 |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| JP2023501539A (ja) | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用 |
| BR112022011158A2 (pt) * | 2019-12-12 | 2022-08-30 | Ignite Immunotherapy Inc | Vírus vaccinia oncolítico variante e métodos de uso do mesmo |
| JP2023539454A (ja) | 2020-08-12 | 2023-09-14 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム |
| US20240102912A1 (en) * | 2020-11-09 | 2024-03-28 | Thrive Bioscience, Inc. | Plaque counting assay method |
| JP2023552289A (ja) | 2020-11-19 | 2023-12-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法 |
| EP4329786A4 (en) | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| WO2026029972A1 (en) * | 2024-07-30 | 2026-02-05 | Gibson Oncology, Llc | Microcrystalline polymorphs of lmp744 and uses thereof |
| WO2026029971A1 (en) * | 2024-07-30 | 2026-02-05 | Gibson Oncology, Llc | Microcrystalline polymorphs of lmp400 and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001072281A2 (en) * | 2000-03-24 | 2001-10-04 | Biosphere Medical Inc. | Microspheres for active embolization |
| WO2004014314A2 (en) * | 2002-08-12 | 2004-02-19 | David Kirn | Methods and compositions concerning poxviruses and cancer |
| EP1933857A2 (en) * | 2005-09-07 | 2008-06-25 | Jennerex Biotherapeutics ULC | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| US9919047B2 (en) * | 2011-01-04 | 2018-03-20 | Sillajen, Inc. | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
| ES2847305T3 (es) * | 2013-08-22 | 2021-08-02 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapias inmunooncolíticas |
-
2016
- 2016-09-02 HK HK18114315.9A patent/HK1255192A1/zh unknown
- 2016-09-02 CA CA2996120A patent/CA2996120C/en active Active
- 2016-09-02 EP EP16844635.9A patent/EP3347460A4/en not_active Withdrawn
- 2016-09-02 CN CN201680064990.2A patent/CN108350434B/zh active Active
- 2016-09-02 KR KR1020187009770A patent/KR102674362B1/ko active Active
- 2016-09-02 JP JP2018531280A patent/JP6895968B2/ja not_active Expired - Fee Related
- 2016-09-02 WO PCT/KR2016/009866 patent/WO2017043815A1/en not_active Ceased
- 2016-09-02 US US15/758,689 patent/US10646524B2/en active Active
- 2016-09-02 AU AU2016320355A patent/AU2016320355B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer | |
| Zhang et al. | Interplay between inflammatory tumor microenvironment and cancer stem cells | |
| Shen et al. | Persistent cancer cells: the deadly survivors | |
| Shan et al. | Mechanism and strategies of immunotherapy resistance in colorectal cancer | |
| Kowalsky et al. | Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade | |
| Vilgelm et al. | Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy | |
| Takeda et al. | A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy | |
| JP6949131B2 (ja) | 治療用ｒｎａ | |
| Fridlender et al. | Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms | |
| Cui et al. | Generation of effector CD8+ T cells and their conversion to memory T cells | |
| Bao et al. | The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis | |
| Di Carlo et al. | Depletion of slow-cycling PDGFRα+ ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis | |
| Hashimoto et al. | Type I IFN gene delivery suppresses regulatory T cells within tumors | |
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| JP2022524391A (ja) | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 | |
| Karagiannidis et al. | G-CSF and G-CSFR modulate CD4 and CD8 T cell responses to promote colon tumor growth and are potential therapeutic targets | |
| CN114729358A (zh) | 涉及miRNA-193a的新疗法 | |
| WO2018228538A1 (zh) | 重组单纯疱疹病毒及其制备方法和应用 | |
| JP2018526450A (ja) | サイトカインおよびカルボキシルエステラーゼを発現する腫瘍溶解性改変ワクシニアウイルス、および、その使用方法 | |
| Ma et al. | High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment | |
| Perales-Puchalt et al. | IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment | |
| Du et al. | Therapeutic potential of targeting stromal crosstalk-mediated immune suppression in pancreatic cancer | |
| JP2019532047A (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| Xing et al. | Factors impacting the benefits and pathogenicity of Th17 cells in the tumor microenvironment | |
| Sutanto et al. | Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity |